Clinical Report: RNA-Directed Strategy Enhances Diagnosis in IEI Patients
Overview
This study presents a structured RNA-guided approach that improved the diagnostic yield in patients with unresolved inborn errors of immunity (IEI). The method successfully identified conclusive diagnoses in 2 out of 22 patients previously deemed inconclusive by standard genetic testing.
Background
Inborn errors of immunity (IEI) represent a diverse group of over 550 disorders linked to more than 500 genes, with diagnostic rates ranging from 15% to 70%. The complexity of these disorders often leads to missed diagnoses due to variants of uncertain significance and limitations of current genetic testing methods. Enhancing diagnostic accuracy is crucial for timely treatment and management of these patients.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
RNA-guided variant interpretation led to a conclusive diagnosis in 2 out of 22 patients with unresolved IEI.
A splice variant in IKBKG was identified, explaining the phenotype of one male patient.
A pathogenic splice variant in CYBB was detected in a female patient, linked to skewed X-inactivation.
A deep-intronic variant in NFKB1 was found, activating a cryptic splice site consistent with NFKB1 haploinsufficiency.
Current genetic testing methods yield a diagnostic rate of approximately 38% for IEI.
RNA-sequencing can reveal functional effects of genetic variants, potentially increasing diagnostic yield by 4-12%.
Clinical Implications
Integrating RNA-sequencing into routine diagnostics may enhance the identification of causative variants in IEI patients. This approach could lead to more accurate diagnoses and better-targeted treatments.
Conclusion
Revise to reflect only the findings presented in the study without broader implications.
by Willem T. K. Maassen, Lotte C. E. T. Pape, Tim Niemeijer, Anne-Margriet Heijink, Martine T. Meems-Veldhuis, Daniëlle J. Boerrigter, Gerben van der Vries, Helga Westers, Lennart F. Johansson, Kasper J. van der Velde, Morris A. Swertz, Lude Franke, Geertje E. Legger, Annechien J. A. Lambeck, Abraham Rutgers, Iris H. Jonkers, Mariëlle E. van Gijn, Evelien Zonneveld-Huijssoon
Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.
The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.
“And when one of these measles cases ends up in a low-immunization community, that's when the ember really has a chance to expand and become a wildfire.”
